Michael Pittaro, MD
Clinical Cardiac Electrophysiology · Stamford, CTNPI 1891806857
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $66,548 of the $69,588 with a category attached, or 95.6%. Abbott accounts for 95.8% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $21,108 and has fallen 97.9% since, to $439 in 2025.
Across 192 payments — averaging $362.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$67K
- Medtronic$779
- Novartis$626
- Biosense Webster, Inc.$391
- Johnson & Johnson$210
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$128
- plus $787 from 20 others
Across 22 payments — averaging $394.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$5K
- Biotronik Inc.$4K
What the payments were for
- Consulting fees$66,54896%
- Travel & lodging$4211%
- Food & beverage$2,6144%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 70 | $66,665 |
| Medtronic | 12 | $779 |
| Novartis | 37 | $626 |
| Biosense Webster, Inc. | 15 | $391 |
| Johnson & Johnson | 14 | $210 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $128 |
| Edwards Lifesciences | 1 | $114 |
| Boehringer Ingelheim | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 5 | $71 |
| Acutus Medical, Inc. | 4 | $70 |
| AstraZeneca | 5 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Biotronik Inc. | 2 | $42 |
| Amgen | 1 | $33 |
| Bridgebio Pharma, Inc. | 1 | $33 |
| Pfizer | 2 | $29 |
| Cardiva Medical, Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Merck | 1 | $21 |
| Preventice Services, LLC | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Accent Pacemaker$23,299
- ALLURE$9,138
- Assurity Pacemaker$8,888
- ACCENT$8,500
- Endurity Pacemaker$6,392
- Quadra Allure MP RF CRT Pacemkr$2,340
- Unify Assura CRT Defibrillator$1,712
- Absorb GT1$1,700
- Fortify Assura, Ellipse ICD$1,605
- ALLURE QUADRA$1,488
- GALLANT$1,488
- Micra$120
- LINQ II$119
- Carto 3$111
How this compares
$69,588 in reported general payments places this provider in the 85th percentile of 47 clinical cardiac electrophysiology providers in Connecticut.
See all clinical cardiac electrophysiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 295 | $388,963 |
| EntrestoSacubitril/Valsartan | 74 | $127,675 |
| XareltoRivaroxaban | 29 | $37,230 |
| FarxigaDapagliflozin Propanediol | 15 | $17,556 |
| JardianceEmpagliflozin | 11 | $12,418 |
| Amiodarone Hcl | 100 | $3,319 |
| Metoprolol Succinate | 188 | $2,893 |
| Dofetilide | 19 | $2,838 |
| Flecainide Acetate | 48 | $2,152 |
| Atorvastatin Calcium | 190 | $1,915 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 47 | $1,188 |
| Amlodipine Besylate | 96 | $686 |
| Rosuvastatin Calcium | 31 | $605 |
| Losartan Potassium | 76 | $554 |
| Carvedilol | 54 | $545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $29 | $388,963295 claims |
| NovartisEntresto | $626 | $127,67574 claims |
| Johnson & JohnsonXarelto | $210 | $37,23029 claims |
| AstraZenecaFarxiga | $63 | $17,55615 claims |
| Boehringer IngelheimJardiance | $82 | $12,41811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 47 clinical cardiac electrophysiology providers in Connecticut.
Other clinical cardiac electrophysiology in Stamford
- Hamed EmamiStamford$20K
- Shuaib LatifStamford$7K
- Sandhya DhruvakumarStamford$3K
- Joshua LaderStamford$2K
- Joseph Dell OrfanoHartford$160K
- Paras BhattNorwich$139K
- Steven ZweibelHartford$125K
- Murali ChiravuriFairfield$101K
- James FreemanNew Haven$87K
- Jude ClancyMiddletown$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.